# Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/atezolizumab-with-or-without-bevacizumab-in-unresectable-hepatocellular/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael S. Lee,Baek‐Yeol Ryoo,Chih‐Hung Hsu,Kazushi Numata,Stacey Stein,Wendy Verret,Stephen P. Hack,Jessica Spahn,Bo Liu,Heba Abdullah,Yulei Wang,Aiwu Ruth He,Kyung-Hun Lee,Y-J. Bang,Johanna C. Bendell,Yee Chao,J-S Chen,Hyun Cheol Chung,S. Lindsey Davis,Atul Dev,Edward Gane,Ben George,Aiwu Ruth He,Howard S. Höchster,C-H Hsu,Masafumi Ikeda,Jes Chauviere Lee,M. Lee,Amit Mahipal,Gulam A. Manji,Manabu Morimoto,Kazushi Numata,Michael J. Pishvaian,Shukui Qin,David P. Ryan,B-Y Ryoo,Naoki Sasahira,Stacey Stein,John H. Strickler,N. C. Tebbutt |
| Citations | 569 |
| DOI | 10.1016/s1470-2045(20)30156-x |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3033218405 |
| PMID | 32502443 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Manabu Morimoto](https://scholariq.org/researchers/manabu-morimoto/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.